In thyroid eye disease, cells in the eye socket show higher levels of a protein called IGF-1R, which promotes swelling, fat growth, and immune cell activity, leading to bulging eyes and tissue damage.
Claim Context
Thyroid eye disease is strongly associated with elevated expression of the insulin-like growth factor-1 receptor (IGF-1R) on orbital fibroblasts, T cells, and B cells, which drives inflammation, glycosaminoglycan secretion, adipogenesis, and lymphocyte survival, contributing to proptosis and tissue remodeling in patients with Graves' disease.
“IGF-1R expression levels are elevated in orbital fibroblasts, T cells, and B cells from TED patients compared to normal levels. IGF-1R participates in cellular growth, proliferation, and anti-apoptotic processes through multiple signaling pathways and molecular mechanisms, playing a key role in the pathogenesis of TED.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all published cohort and case-control studies could quantify the strength and consistency of the association between IGF-1R expression levels and TED severity across diverse populations.
A systematic review and meta-analysis of all peer-reviewed cohort and case-control studies measuring IGF-1R expression in orbital tissue or peripheral blood of TED patients versus controls, using standardized assays (e.g., qPCR, flow cytometry), with pooled analysis of standardized mean differences in IGF-1R levels and correlation with CAS scores and proptosis measurements.
A randomized controlled trial of IGF-1R inhibition could determine whether reducing IGF-1R signaling directly reduces disease activity and structural changes in TED.
A double-blind, placebo-controlled trial of 150 adults with active TED (CAS ≥3), randomized to teprotumumab (10 mg/kg IV every 3 weeks for 24 weeks) or placebo, with primary outcomes of change in proptosis (mm) and CAS score at 24 weeks, and secondary outcomes of orbital fat volume (MRI), serum IGF-1R levels, and TRAb titers.
A prospective cohort could determine whether baseline IGF-1R expression predicts future TED progression or treatment response.
A prospective cohort of 300 patients with newly diagnosed Graves' disease, measuring IGF-1R expression in peripheral blood mononuclear cells at baseline and following them for 24 months to assess incidence and severity of TED, adjusting for smoking, TRAb levels, and thyroid function.
A case-control study could compare IGF-1R expression levels between TED patients and Graves' patients without eye disease to isolate ocular-specific associations.
A matched case-control study comparing IGF-1R expression (via flow cytometry) in orbital fibroblasts and peripheral T cells from 50 TED patients and 50 Graves' patients without ophthalmopathy, matched for age, sex, TRAb titer, and disease duration.
A cross-sectional study could describe the prevalence and magnitude of IGF-1R elevation in TED patients at a single time point.
A cross-sectional study measuring IGF-1R expression in orbital tissue biopsies and serum from 100 consecutive TED patients and 50 healthy controls using standardized immunohistochemistry and ELISA, with correlation to clinical activity scores.